AccScience Publishing / AN / Online First / DOI: 10.36922/AN025140026
Submit to AN
Cite this article
5
Download
22
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
LETTER TO EDITOR

A novel relationship between norepinephrine and glutamate in aging: Implications for neurodegenerative disorders

Paul J. Fitzgerald1*
Show Less
1 Independent Researcher, West Lafayette, Indiana, United States of America
Advanced Neurology, 025140026 https://doi.org/10.36922/AN025140026
Received: 5 April 2025 | Accepted: 15 April 2025 | Published online: 2 May 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Conflict of interest
The author declares that he has no known competing financial interests or personal relationships that influenced the work reported in this paper.
References
  1. Weinshenker D. Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211-223. doi: 10.1016/j.tins.2018.01.010

 

  1. Fitzgerald PJ. Is elevated norepinephrine an etiological factor in some cases of Alzheimer’s disease? Curr Alzheimer Res. 2010;7(6):506-516. doi: 10.2174/156720510792231775

 

  1. Fitzgerald PJ. Is elevated norepinephrine an etiological factor in some cases of Parkinson’s disease? Med Hypotheses. 2014;82(4):462-469. doi: 10.1016/j.mehy.2014.01.026

 

  1. Gannon M, Wang Q. Complex noradrenergic dysfunction in Alzheimer’s disease: Low norepinephrine input is not always to blame. Brain Res. 2019;1702:12-16. doi: 10.1016/j.brainres.2018.01.001

 

  1. Mather M. Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer’s disease? Semin Cell Dev Biol. 2021;116:108-124. doi: 10.1016/j.semcdb.2021.05.013

 

  1. Fitzgerald PJ. Norepinephrine may oppose other neuromodulators to impact Alzheimer’s disease. Int J Mol Sci. 2021;22(14):7364. doi: 10.3390/ijms22147364

 

  1. Fitzgerald PJ. Elevated norepinephrine may interact with alpha-synuclein to promote Parkinson’s disease and DLB. Acta Neurol Scand. 2022;145(1):3-4. doi: 10.1111/ane.13526

 

  1. Raskind MA, Peskind ER, Veith RC, Beard JC, Gumbrecht G, Haltert JB. Increased plasma and cerebrospinal fluid norepinephrine in older men: Differential suppression by clonidine. J Clin Endocrinol Metab. 1988;66(2):438-443. doi: 10.1210/jcem-66-2-438

 

  1. Fitzgerald PJ. Diurnal build-up of norepinephrine may underlie sundowning in dementia. Clin Neurol Neurosurg. 2021;206:106702. doi: 10.1016/j.clineuro.2021.106702

 

  1. Yun AJ, Lee PY, Bazar KA. Many diseases may reflect dysfunctions of autonomic balance attributable to evolutionary displacement. Med Hypotheses. 2004;62(6):847-851. doi: 10.1016/j.mehy.2004.02.006

 

  1. Mather M, Clewett D, Sakaki M, Harley CW. Norepinephrine ignites local hotspots of neuronal excitation: How arousal amplifies selectivity in perception and memory. Behav Brain Sci. 2016;39:e200. doi: 10.1017/S0140525X15000667

 

  1. Alexander GM, Grothusen JR, Gordon SW, Schwartzman RJ. Intracerebral microdialysis study of glutamate reuptake in awake, behaving rats. Brain Res. 1997;766(1-2):1-10. doi: 10.1016/S0006-8993(97)00519-2

 

  1. Devilbiss DM, Waterhouse BD. Norepinephrine exhibits two distinct profiles of action on sensory cortical neuron responses to excitatory synaptic stimuli. Synapse. 2000;37(4):273-282. doi: 10.1002/1098-2396(20000915)37:4<273:AID-SYN4>3.0.CO;2-#

 

  1. Mouradian RD, Sessler FM, Waterhouse BD. Noradrenergic potentiation of excitatory transmitter action in cerebrocortical slices: Evidence for mediation by an alpha 1 receptor-linked second messenger pathway. Brain Res. 1991;546(1):83-95. doi: 10.1016/0006-8993(91)91162-T

 

  1. Hayward LF, Mueller PJ, Hasser EM. Adrenergic receptors. In: Encyclopedia of Endocrine Diseases. Cambridge: Academic Press; 2004. p. 112-115. doi: 10.1016/B0-12-475570-4/00039-1

 

  1. Yi H, Talmon G, Wang J. Glutamate in cancers: From metabolism to signaling. J Biomed Res. 2020;34(4):260-270. doi: 10.7555/JBR.34.20190037

 

  1. Lee JYS, Ng JH, Saffari SE, Tan EK. Parkinson’s disease and cancer: A systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender. Aging (Albany NY). 2022;14(5):2148-2173. doi: 10.18632/aging.203932

 

  1. Majd S, Power J, Majd Z. Alzheimer’s disease and cancer: When two monsters cannot be together. Front Neurosci. 2019;13:155. doi: 10.3389/fnins.2019.00155

 

  1. Fatuzzo I, Niccolini GF, Zoccali F, et al. Neurons, nose, and neurodegenerative diseases: Olfactory function and cognitive impairment. Int J Mol Sci. 2023;24(3):2117. doi: 10.3390/ijms24032117

 

  1. Kubota T, Anzawa N, Hirota K, Yoshida H, Kushikata T, Matsuki A. Effects of ketamine and pentobarbital on noradrenaline release from the medial prefrontal cortex in rats. Can J Anaesth. 1999;46(4):388-392. doi: 10.1007/BF03013235

 

  1. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921-2927. doi: 10.1523/JNEUROSCI.17-08-02921.1997

 

Next article in this issue
Share
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept